About one-third of all drugs approved by the U.S. Food and Drug Administration target G protein-coupled receptors (GPCRs), a family of more than 800 cell-surface receptors that regulate a wide range of vital functions, including blood pressure, heart rate and immunity.

Welcome to Harvard Medicine Insights. In this issue, we feature two advances that show the power of scientific collaboration: a new way to switch off G protein-coupled receptors by removing them from ...

Researchers here propose that greater efforts should be devoted to considering the variety of G-protein coupled receptors (GPCRs) as a regulatory network in the matter of aging and age-related disease...

The next revolution in cancer medicine may not come from a new drug molecule but from a family of proteins that scientists have quietly overlooked for decades. G protein-coupled receptors, or GPCRs,

Kadoki et al. developed GPCR-seq, a high-throughput platform to identify how the gut senses environmental chemicals. They discovered gut microbial products that activate intestinal receptors, triggeri...

G protein–coupled receptors (GPCRs) are pivotal sensors of the mechanical environment, yet how they sense and transduce physical stimuli into bioch...

Researchers have outlined a bold plan for slowing aging by targeting one of the body's most important cellular communication systems. In a new paper published today in Frontiers in Science, scientists describe how novel therapies that modulate GPCR signaling could one day help delay multiple age-related diseases at once-potentially extending healthy years of life. GPCRs are widespread throughout the body and regulate many essential biological processes. Age-related changes in GPCR signaling are linked to multiple hallmarks of aging and many major chronic diseases. The authors propose that therapies designed to rebalance GPCR signaling across tissues could therefore help counter some of the key biological processes that drive aging and age-related disease. What's most exciting about this network-level GPCR approach is its ability to influence many of the biological systems that change with age at the same time." Prof. Stuart Maudsley, Senior Author, H. Lee Moffitt Cancer Center, Florida This network-level approach-targeting multiple GPCR pathways across the body rather than a single receptor or disease-could give rise to highly personalized treatments based on individual aging biomarkers, the researchers say, as well as advanced strategies that modulate GPCR signaling across different tissues and pathways. These interventions could also complement other emerging longevity...

G protein-coupled receptors (GPCRs) modulate diverse hormonal, metabolic, neural, and immunological signaling processes. Their age-dependent decline accounts...

Researchers have proposed a novel approach to slowing aging by targeting G protein-coupled receptors (GPCRs), which are widespread throughout the body and regulate essential biological processes. In a paper published in Frontiers in Science, scientists outline how therapies that modulate GPCR signaling could potentially delay multiple age-related diseases simultaneously, extending healthy years of life. GPCRs play a critical role in regulating hormones, metabolism, brain function, immune responses, and other key systems. Age-related changes in GPCR signaling are linked to several hallmarks of aging, including chronic inflammation, reduced cellular energy production, genomic dysregulation, and impaired cellular communication. The authors suggest that rebalancing GPCR signaling across tissues could counteract these aging processes. This network-level approach, targeting multiple GPCR pathways rather than a single receptor or disease, could lead to highly personalized treatments based on individual aging biomarkers. Such therapies could complement other longevity strategies like metabolic therapies, regenerative medicine, and anti-inflammatory treatments. The researchers emphasize that GPCRs are highly 'druggable' and could provide a powerful platform for developing therapies aimed at extending healthspan and preventing age-related diseases. Advances in artificial intelligence, systems biology, and precision medicine are enabling new GPCR-based therapies that target the biological mechanisms underlying aging. Co-authors highlighted the potential for personalization, noting that individual biological complexity can be leveraged to develop tailored treatments by identifying drivers of processes at the systems level. They also mentioned that a triad of human experts, glass-box AI systems, and experimental validation could facilitate more precise interventions designed around prevention and long-term health maintenance. The international team believes this approach could transform how we prevent and treat age-related diseases, potentially making conditions like Alzheimer's, diabetes, and cardiovascular diseases preventable or treatable rather than inevitable. The research, led by Prof. Stuart Maudsley from H. Lee Moffitt Cancer Center, represents a promising new direction in longevity science.